Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
Prestige Consumer Healthcare Inc (NYSE: PBH) maintains leadership in over-the-counter healthcare through trusted brands like Clear Eyes and Summer’s Eve. This news hub provides investors and industry professionals with essential updates on corporate developments, regulatory milestones, and market strategies.
Access comprehensive coverage of PBH’s operational updates including earnings announcements, product innovations, and supply chain initiatives. Our curated news collection offers context for understanding the company’s position in competitive OTC markets across North America and international regions.
Key updates feature strategic partnerships, quality assurance developments, and responses to evolving consumer health trends. The resource serves as a centralized reference for tracking PBH’s commitment to product stewardship and operational efficiency in dynamic healthcare markets.
Bookmark this page for streamlined access to press releases and analysis on PBH’s market navigation. Regular updates ensure stakeholders maintain current awareness of corporate initiatives impacting long-term value creation in consumer healthcare.
Prestige Consumer Healthcare (NYSE:PBH) has announced its participation in the Barclays Global Consumer Staples Conference on Thursday, September 5, 2024, at 2:15 p.m. ET. The company will present at this significant industry event, offering insights into its operations and strategy.
Interested parties can access a live webcast of the presentation through the company's official website under the 'Investors' section and 'Events and Presentations' tab. For those unable to attend the live event, a replay option will be available on the company's website following the presentation. This announcement highlights Prestige Consumer Healthcare's commitment to investor relations and transparency in its business operations.
Prestige Consumer Healthcare Inc. (NYSE:PBH) reported Q1 fiscal 2025 results with revenue of $267.1 million, down 4.4% year-over-year but ahead of expectations. EPS was $0.98 and adjusted EPS was $0.90, compared to $1.06 in the prior year. Cash from operations increased 13.9% to $54.8 million. The company reduced debt by $35 million and repurchased $26 million in shares.
Key highlights:
- North American OTC Healthcare segment revenue decreased 5.6% to $232.3 million
- International OTC Healthcare segment revenue increased 5.0% to $34.8 million
- Free cash flow increased to $53.6 million
- Net debt position of approximately $1.1 billion with a leverage ratio of 2.8x
The company reaffirmed its full-year fiscal 2025 outlook, expecting revenue of $1,125 to $1,140 million, organic revenue growth of approximately 1%, and adjusted EPS of $4.40 to $4.46.
Prestige Consumer Healthcare announced its fiscal 2025 first quarter earnings release will be issued on August 8, 2024, before the market opens.
The company will host a conference call to discuss the results at 8:30 a.m. ET the same day. Participants can join the live Internet webcast via the Investor Relations page on the company's website. Phone participants need to register to receive dial-in details and a unique pin. It is recommended to join the call 10 minutes early. A replay of the conference call will be available for a week on the Investor Relations page.
Prestige Consumer Healthcare (NYSE:PBH) will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on June 10, 2024, at 1:30 p.m. ET. Interested parties can access a live webcast of the event via the company's website under the 'Investors' section or use the provided link. A replay will be available for those unable to attend the live session.
Prestige Consumer Healthcare (NYSE: PBH) reported its fiscal year 2024 results with $277.0 million in Q4 revenue and $1,125.4 million for the full year, a slight 0.2% increase from the previous year. Q4 net income was $49.5 million, a significant improvement from the previous year's net loss of $240.6 million. The company's leverage ratio was reduced to 2.8x, below its long-term target. The Board authorized a new $300 million share repurchase program. For fiscal 2025, Prestige anticipates a 1% organic revenue growth and an EPS range of $4.40 to $4.46. Ongoing supply chain issues, particularly in eye care products, affected Q4 performance but are expected to improve mid-2025.
FAQ
What is the current stock price of Prestige Consmr Healthcare (PBH)?
What is the market cap of Prestige Consmr Healthcare (PBH)?
